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background: Outcomes of transcatheter aortic valve replacement (TAVR) in patients with end-stage renal disease (ESRD) on renal replacement 
therapy (RRT) are not known since they were excluded from the pivotal clinical trials. Do patients with ESRD have acceptable short-term outcomes to 
warrant TAVR?
Methods: All patients with ESRD on RRT who underwent TAVR and were entered into the STS/ACC Transcatheter Valve Therapy (TVT) Registry were 
analyzed and compared to non-dialysis patients undergoing TAVR.
results: Overall, 383/8,670 (4.4%) of TAVR patients had ESRD on dialysis across 230 sites from November, 2011 through June, 2013. Compared 
with non-dialysis patients, ESRD patients were younger (78 vs. 84 years, p<.0001), but had a higher median STS predicted risk of mortality (13.8% 
vs. 6.8%,p <.0001). Compared with non-dialysis patients, dialysis patient had similar device success (88.8% vs. 90%, p=0.25) but significantly 
higher in hospital mortality (9.7% vs. 5.3%, p=0.0002); major bleeding (7.7% vs. 3.3%, p<0.001); and vascular complications (9.5% vs 6.1%, 
p=0.006). Rates of stroke were similar in ESRD vs. non dialysis patients 1.6% vs. 2.0%, (p=0.6). Dialysis patients receiving TAVR had lower observed 
incidence of in-hospital mortality than predicted [observed/expected (O/E ) ratio =0.7], with a risk adjusted mortality of 6.8 %.
conclusion: Among patients undergoing TAVR in the US, those with ESRD on dialysis had a higher incidence of in -hospital mortality and 
complications than those without ESRD. However, ESRD patients receiving TAVR had lower mortality than expected for surgical valve replacement. 
Thus, TAVR may be a viable treatment in selected ESRD patients, pending longer-term follow up.
